Q4 2024 Earnings Call Transcript March 12, 2025 Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.15 ...

Late-breaking results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) found adolescent patients (ages 12 to under 18) with severe alopecia areata (AA) treated with once-daily ...

Significantly more adolescent patients receiving baricitinib had hair regrowth compared with patients receiving placebo.

In an interview with Brittany Craiglow, MD, FAAD, dermatologist at Dermatology Physicians of Connecticut in Fairfield, she advocates for combination therapies using baricitinib to treat pediatric ...

A research group, led by Dr. Pavel Majer from IOCB Prague, in collaboration with the laboratories of Barbara Slusher and Louis Garza at Johns Hopkins University, have developed a compound that could ...

For adolescents with severe alopecia areata (AA), baricitinib is efficacious for hair regrowth, according to a study ...

Ivarmacitinib at both 4 mg and 8 mg doses was found to be efficacious in treating alopecia areata in a phase 3 trial.

Alopecia areata, an autoimmune condition, can also occur comorbidly with CKD. Kidney disease can cause a variety of complications that can lead to telogen effluvium and result in alopecia.